

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## Ausupreme International Holdings Limited

澳至尊國際控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2031)**

### ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025

#### RESULTS

The board (the “**Board**”) of directors (the “**Directors**”) of Ausupreme International Holdings Limited (the “**Company**”) is pleased to present the unaudited condensed consolidated results of the Company and its subsidiaries (together as the “**Group**”) for the six months ended 30 September 2025 (the “**Period**”), together with the relevant comparative figures as follows:

#### CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

*For the six months ended 30 September 2025*

		Six months ended 30 September	
	Notes	2025 HK\$'000 (Unaudited)	2024 HK\$'000 (Unaudited)
Revenue	4(a)	144,972	126,540
Cost of sales		(18,155)	(16,193)
<b>Gross profit</b>		<b>126,817</b>	<b>110,347</b>
Other income	5(a)	778	1,087
Other gains and losses, net	5(b)	555	(224)
Selling and distribution expenses		(87,278)	(78,460)
General and administrative expenses		(18,697)	(16,249)
Finance costs	6	(494)	(562)

		Six months ended 30 September	
		2025	2024
	Notes	HK\$'000 (Unaudited)	HK\$'000 (Unaudited)
<b>Profit before taxation</b>		<b>21,681</b>	15,939
Income tax expense	7	<u>(3,780)</u>	<u>(2,700)</u>
<b>Profit for the period</b>	8	<u><b>17,901</b></u>	<u>13,239</u>
<b>Other comprehensive income:</b>			
Item that will not be reclassified to profit or loss:			
— Fair value gain on investments in equity instruments at fair value through other comprehensive income (“FVTOCI”)		<b>209</b>	934
Item that may be reclassified subsequently to profit or loss:			
— Exchange differences arising on translation of foreign operations		<u><b>351</b></u>	<u>512</u>
Other comprehensive income for the period, net of tax		<u><b>560</b></u>	<u>1,446</u>
<b>Total comprehensive income for the period</b>		<u><b>18,461</b></u>	<u>14,685</u>
		<i>HK Cents</i>	<i>HK Cents</i>
Earnings per share	10		
— Basic		<b>2.35</b>	1.74
— Diluted		<u><b>N/A</b></u>	<u>N/A</u>

# CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 September 2025

		As at 30 September 2025 <i>Notes</i> <b>HK\$'000</b> (Unaudited)	As at 31 March 2025 <i>HK\$'000</i> (Audited)
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment		<b>56,396</b>	57,337
Right-of-use assets		<b>17,528</b>	17,895
Investment properties		<b>9,114</b>	9,452
Equity investment at FVTOCI	11	<b>2,760</b>	2,551
Deferred tax assets		<b>681</b>	680
		<b>86,479</b>	87,915
<b>CURRENT ASSETS</b>			
Inventories		<b>20,913</b>	19,057
Trade and other receivables	12	<b>40,200</b>	32,606
Time deposits		<b>18,622</b>	9,996
Cash and cash equivalents		<b>82,619</b>	78,723
		<b>162,354</b>	140,382
<b>CURRENT LIABILITIES</b>			
Trade and other payables	13	<b>14,979</b>	14,337
Bank borrowing		<b>1,837</b>	2,057
Dividend payable		<b>15,257</b>	17
Lease liabilities		<b>11,238</b>	11,681
Provisions		<b>720</b>	699
Income tax payable		<b>2,925</b>	784
		<b>46,956</b>	29,575
<b>NET CURRENT ASSETS</b>		<b>115,398</b>	110,807
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>201,877</b>	198,722

		As at 30 September 2025 <i>Notes</i> <b>HK\$'000</b> (Unaudited)	As at 31 March 2025 <i>HK\$'000</i> (Audited)
<b>NON-CURRENT LIABILITIES</b>			
Lease liabilities		6,661	6,706
Provisions		<u>789</u>	<u>810</u>
		<u>7,450</u>	<u>7,516</u>
<b>NET ASSETS</b>		<u><b>194,427</b></u>	<u>191,206</u>
<b>CAPITAL AND RESERVES</b>			
Share capital	14	7,620	7,620
Reserves		<u>186,807</u>	<u>183,586</u>
<b>TOTAL EQUITY</b>		<u><b>194,427</b></u>	<u>191,206</u>

# CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 September 2025

	Attributable to owners of the Company							Total HK\$'000
	Share capital HK\$'000	Share premium HK\$'000	Equity investment at FVTOCI reserve HK\$'000	Exchange reserve HK\$'000	Capital reserve HK\$'000	Other reserve HK\$'000	Retained earnings HK\$'000	
At 1 April 2025	7,620	91,288	(4,643)	(2,047)	1,546	(250)	97,692	191,206
Profit for the period	—	—	—	—	—	—	17,901	17,901
Other comprehensive income	—	—	209	351	—	—	—	560
Total comprehensive income for the period	—	—	209	351	—	—	17,901	18,461
Dividends recognised as distribution (Note 9)	—	—	—	—	—	—	(15,240)	(15,240)
<b>Balance at 30 September 2025 (Unaudited)</b>	<b>7,620</b>	<b>91,288</b>	<b>(4,434)</b>	<b>(1,696)</b>	<b>1,546</b>	<b>(250)</b>	<b>100,353</b>	<b>194,427</b>

	Attributable to owners of the Company							Total HK\$'000
	Share capital HK\$'000	Share premium HK\$'000	Equity investment at FVTOCI reserve HK\$'000	Exchange reserve HK\$'000	Capital reserve HK\$'000	Other reserve HK\$'000	Retained earnings HK\$'000	
At 1 April 2024	7,620	91,288	(5,304)	(1,961)	1,546	—	85,021	178,210
Profit for the period	—	—	—	—	—	—	13,239	13,239
Other comprehensive income	—	—	934	512	—	—	—	1,446
Total comprehensive income for the period	—	—	934	512	—	—	13,239	14,685
Dividends recognised as distribution (Note 9)	—	—	—	—	—	—	(15,240)	(15,240)
<b>Balance at 30 September 2024 (Unaudited)</b>	<b>7,620</b>	<b>91,288</b>	<b>(4,370)</b>	<b>(1,449)</b>	<b>1,546</b>	<b>—</b>	<b>83,020</b>	<b>177,655</b>

# NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

*For the six months ended 30 September 2025*

## 1. CORPORATE INFORMATION

The Company was incorporated as an exempted company with limited liability in the Cayman Islands on 17 April 2015 and is an investment holding company. Its registered office is located at Windward 3, Regatta Office Park, PO Box 1350, Grand Cayman KY1-1108, Cayman Islands. The address of the Company's principal place of business is Office E, 30/F., EGL Tower, 83 Hung To Road, Kwun Tong, Kowloon, Hong Kong.

The Group is a Hong Kong-based brand builder, retailer and wholesaler of health and personal care products focusing on the development, marketing, sales and distribution of the branded products managed by the Group.

The issued ordinary shares of the Company were initially listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 12 September 2016 (the “**Listing**”).

The unaudited condensed consolidated interim financial statements of the Group for the six months ended 30 September 2025 (the “**Condensed Consolidated Interim Financial Statements**”) are presented in Hong Kong dollars (“**HK\$**”) and all values are rounded to the nearest thousand except when otherwise indicated.

## 2. BASIS OF PREPARATION

The unaudited Condensed Consolidated Interim Financial Statements have been prepared in accordance with Hong Kong Accounting Standard (“**HKAS**”) 34 “Interim Financial Reporting” issued by the Hong Kong Institute of Certified Public Accountants (the “**HKICPA**”) as well as the applicable disclosure requirements of Appendix D2 to the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”).

The unaudited Condensed Consolidated Interim Financial Statements have been prepared on the historical cost basis.

The unaudited Condensed Consolidated Interim Financial Statements do not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the annual report of the Company for the year ended 31 March 2025.

The Condensed Consolidated Interim Financial Statements have not been audited nor reviewed by the independent auditor of the Company but have been reviewed by the audit committee of the Board (the “**Audit Committee**”).

### 3. PRINCIPAL ACCOUNTING POLICIES

The accounting policies and methods of computation used in the unaudited Condensed Consolidated Interim Financial Statements are the same as those followed in the preparation of the Group's financial statements for the year ended 31 March 2025, except as described below.

In the current reporting period, the Group has applied, for the first time, the following amendments to Hong Kong Financial Reporting Standards (the “HKFRSs”) issued by the HKICPA that are relevant for the preparation of the Condensed Consolidated Interim Financial Statements and mandatorily effective for the annual period beginning on or after 1 April 2025:

Amendments to HKAS 21

Lack of Exchangeability

The application of the amendments to HKFRSs in the current period had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these Condensed Consolidated Interim Financial Statements.

### 4. REVENUE AND SEGMENT REPORTING

#### (a) Revenue

##### (i) Disaggregation of revenue from contracts with customers

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
<b>Types of goods</b>		
Health supplement products	138,589	120,398
Personal care products	5,958	5,766
Honey products	425	376
<b>Total</b>	<b>144,972</b>	<b>126,540</b>
<b>Timing of revenue recognition</b>		
A point in time	144,972	126,540
<b>Sales channel</b>		
Specialty stores	23,197	21,003
Consignment counters	105,184	90,636
E-commerce	10,715	9,966
Other sales channels	5,876	4,935
<b>Total</b>	<b>144,972</b>	<b>126,540</b>

**(ii) Performance obligations for contracts with customers**

Revenue from retail and wholesale of health and personal care products is recognised at a point in time upon the delivery of the health and personal care products to the customers or, in case of consignment sales through consignees, upon collection of the products by end-customers, which is the point of time when customer has the ability to direct the use of products and obtain substantially all of the remaining benefits of the products. The payment terms are generally within 0 to 60 days.

**(iii) Transaction price allocated to the remaining performance obligation for contracts with customers**

All contracts with customers are for periods of one year or less. As permitted under HKFRS 15, the transaction price allocated to these unsatisfied contracts is not disclosed.

**(b) Segment reporting**

Information reported to the Board, being the chief operating decision maker (“CODM”), for the purposes of resource allocation and assessment of segment performance focuses on types of goods or services delivered or provided. No operating segments identified by the CODM have been aggregated in arriving at the reportable segments of the Group.

Specifically, the Group’s reportable and operating segment under HKFRS 8 *Operating Segments* is retail and wholesale of health and personal care products.

Since this is the only reportable and operating segment of the Group, no further analysis thereof is presented. All the revenue of the Group are generated from retail and wholesale of health and personal care products for the six months ended 30 September 2025 and 2024.

**5. OTHER INCOME, OTHER GAINS AND LOSSES, NET**

**(a) Other income**

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Bank interest income on bank deposits	643	891
Dividend Income	43	84
Rental income	23	23
Others	69	89
	<u>778</u>	<u>1,087</u>



(b) Other gains and losses, net

	Six months ended 30 September	
	2025	2024
	<i>HK\$'000</i>	<i>HK\$'000</i>
	(Unaudited)	(Unaudited)
Net foreign exchange gains	1,080	83
Loss from changes in fair value of investment properties, net	(525)	(209)
Loss on deregistration of a subsidiary	—	(98)
	<u>555</u>	<u>(224)</u>

6. FINANCE COSTS

	Six months ended 30 September	
	2025	2024
	<i>HK\$'000</i>	<i>HK\$'000</i>
	(Unaudited)	(Unaudited)
Interest on bank borrowing	27	43
Interest on lease liabilities	467	519
	<u>494</u>	<u>562</u>

## 7. INCOME TAX EXPENSE

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Current tax:		
Hong Kong Profits Tax	2,968	2,045
PRC Enterprise Income Tax	17	5
Macau Complementary Tax	813	697
	<u>3,798</u>	<u>2,747</u>
Over provision in prior year:		
Hong Kong Profits Tax	(9)	—
PRC Enterprise Income Tax	(8)	—
	<u>(17)</u>	<u>—</u>
Deferred tax:		
Current period	<u>(1)</u>	<u>(47)</u>
Total	<u><u>3,780</u></u>	<u><u>2,700</u></u>

### Notes:

Under the two-tiered profits tax rates regime of Hong Kong Profits Tax, the first HK\$2 million of profits of the qualifying group entity will be taxed at 8.25%, and profits above HK\$2 million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5%. Accordingly, the Hong Kong Profits Tax of the qualifying group entity is calculated at 8.25% on the first HK\$2 million of the estimated assessable profits and at 16.5% on the estimated assessable profits above HK\$2 million.

Accordingly, the provision for Hong Kong Profits Tax are calculated at 16.5% of the estimate assessable profits, except for one subsidiary of the Company which is a qualifying corporation under the two-tiered profits tax rates regime.

Taxation for subsidiaries which are outside Hong Kong is charged at the appropriate current rates of taxation ruling in relevant tax jurisdictions.

## 8. PROFIT FOR THE PERIOD

Profit for the period has been arrived at after charging (crediting):

	Six months ended 30 September	
	2025	2024
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Depreciation of:		
— Property, plant and equipment	1,499	1,423
— Right-of-use assets	7,141	6,161
Total depreciation	8,640	7,584
Depreciation included in selling and distribution expenses	(6,901)	(5,892)
Depreciation included in general and administrative expenses	1,739	1,692
Cost of inventories recognised as expense	18,155	16,193
(Reversal of write-down) Write-down of obsolete inventories including in cost of inventories	(200)	307
Consignment expenses ( <i>Note</i> )	44,721	38,798
Advertising and promotion expense including in selling and distribution expenses	3,223	3,905
Donations	88	130

*Note:* Fees paid to consignees for sales of health and personal care products made through the consignment counters are included in “selling and distribution expenses”.

## 9. DIVIDEND

The Board has resolved not to declare an interim dividend for the six months ended 30 September 2025 (2024: Nil).

A final dividend in respect of the year ended 31 March 2025 of HK2 cents (2024: HK2 cents) per ordinary share, amounting to HK\$15,240,000 (2024: HK\$15,240,000) in aggregate, was declared pursuant to the resolution passed by the Board on 26 June 2025 and the approval of the shareholders of the Company (the “**Shareholder(s)**”) at the annual general meeting of the Company held on 12 September 2025. This final dividend was paid on 8 October 2025.

## 10. EARNINGS PER SHARE

The calculation of the basic and diluted earnings per share attributable to the owners of the Company is based on the following data:

	Six months ended 30 September	
	2025	2024
	<i>HK\$'000</i>	<i>HK\$'000</i>
	(Unaudited)	(Unaudited)
Profit for the period attributable to owners of the Company for the purpose of basic and diluted earnings per share	<u>17,901</u>	<u>13,239</u>
	As at 30 September	
	2025	2024
	'000	'000
	(Unaudited)	(Unaudited)
Number of shares:		
Weighted average number of ordinary shares for the purpose of basic and diluted earnings per share	<u>762,000</u>	<u>762,000</u>

No diluted earnings per share for the six months ended 30 September 2025 and 2024 were presented as there were no potential ordinary shares in issue for the six months ended 30 September 2025 and 2024.

## 11. EQUITY INVESTMENT AT FVTOCI

	As at 30 September 2025 <i>HK\$'000</i> (Unaudited)	As at 31 March 2025 <i>HK\$'000</i> (Audited)
Unlisted equity investments in Australia, at fair value	<u>2,760</u>	<u>2,551</u>

The above unlisted equity investments represent the Group's equity interest in Homart Group Pty Limited ("Homart"), which is an unlisted entity in Australia. The Directors have elected to designate these investments in equity instruments as at FVTOCI as they believe that recognising short-term fluctuations in this investment's fair value in profit or loss would be inconsistent with the Group's strategy of holding this investment for long-term purpose and realising its performance potential in the long run.

The fair value of the Group's investment in Homart is determined based on the valuation techniques using market approach by LCH (Asia-Pacific) Surveyors Limited, an independent qualified professional valuer.

## 12. TRADE AND OTHER RECEIVABLES

	As at 30 September 2025 <i>HK\$'000</i> (Unaudited)	As at 31 March 2025 <i>HK\$'000</i> (Audited)
Trade receivables	27,707	21,064
Other receivables	521	625
Deposits and prepayments ( <i>Note</i> )	11,972	10,917
	<u>40,200</u>	<u>32,606</u>

*Note:* Deposits and prepayments comprised mainly rental deposits and prepaid operating expenses.

The Group usually allows a credit period of 0 to 60 days to its trade customers and consignees. The following is an aged analysis of trade receivables, net of allowance for credit losses, presented based on the date of delivery of goods which approximated the respective dates on which revenue was recognised.

	As at 30 September 2025 <i>HK\$'000</i> (Unaudited)	As at 31 March 2025 <i>HK\$'000</i> (Audited)
Within 30 days	11,733	11,083
31–60 days	11,771	9,451
61–90 days	4,002	502
Over 90 days	201	28
	<u>27,707</u>	<u>21,064</u>

The management of the Group closely monitors the credit quality of trade receivables and considers the debtors that are neither past due nor impaired to be of a good credit quality. Before accepting any new customer or consignee, the Group's management will assess the potential customer's or consignee's credit quality and determine the credit limits of each customer or consignee. Credit limits attributable to customers or consignees are reviewed periodically.

The Group has a policy for allowance of impairment loss which is based on the evaluation of collectability and ageing analysis of accounts and on management's judgement including the creditworthiness and the past collection history of each customer or consignee.

Based on the historical experience of the Group, trade receivables that are past due but not impaired are generally recoverable.

### 13. TRADE AND OTHER PAYABLES

	As at 30 September 2025 <i>HK\$'000</i> (Unaudited)	As at 31 March 2025 <i>HK\$'000</i> (Audited)
Trade payables ( <i>Note</i> )	2,090	1,615
Accrued staff costs	9,204	10,004
Other payables and accruals	3,685	2,718
	<u>14,979</u>	<u>14,337</u>

*Note:*

The aged analysis of trade payables, presented based on the invoice date, is as follows:

	As at 30 September 2025 <i>HK\$'000</i> (Unaudited)	As at 31 March 2025 <i>HK\$'000</i> (Audited)
Within 30 days	1,383	675
31–90 days	704	937
Over 90 days	3	3
	<u>2,090</u>	<u>1,615</u>

The average credit period on purchases of goods usually is 0-90 days.

### 14. SHARE CAPITAL

	As at 30 September 2025 (Unaudited)	Share capital <i>HK\$'000</i>	As at 31 March 2025 (Audited)	Share capital <i>HK\$'000</i>
	Number of Shares		Number of Shares	
Ordinary shares of HK\$0.01 each in the share capital of the Company (“Share(s)”) Authorised:				
At beginning of period/year and at end of period/year	<u>2,000,000,000</u>	<u>20,000</u>	<u>2,000,000,000</u>	<u>20,000</u>
Issued and fully paid:				
At beginning of period/year and at end of period/year	<u>762,000,000</u>	<u>7,620</u>	<u>762,000,000</u>	<u>7,620</u>

## 15. MATERIAL RELATED PARTY TRANSACTIONS

For the purposes of these Condensed Consolidated Interim Financial Statements, parties are considered to be related to the Group if the party has the ability, directly or indirectly, to exercise significant influence over the Group in making financial and operating decisions. Related parties may be individuals (being members of key management personnel, significant Shareholders and/or their close family members) or other entities and include entities which are under the significant influence of related parties of the Group where those parties are individuals. Parties are also considered to be related if they are subject to common control.

The Directors are of the view that the following company is a related party that had transactions or balances with the Group as it is controlled by certain Directors:

— Tiger 2023 Limited (“**Tiger**”)

- (i) The Group had the following transactions with related party during the six months ended 30 September 2025 and 2024 which the Directors consider to be material:

	Six months ended 30 September	
	2025	2024
	<i>HK\$'000</i>	<i>HK\$'000</i>
	(Unaudited)	(Unaudited)
Payment of lease liabilities	<u>444</u>	<u>444</u>

The above lease payments were paid to a related company, Tiger, which was controlled by two of the Directors, in accordance with the terms of underlying contracts. The Directors are of the opinion that the above transactions were entered in normal course of business.

- (ii) Lease liabilities payable to Tiger:

	As at 30 September 2025	As at 31 March 2025
	<i>HK\$'000</i>	<i>HK\$'000</i>
	(Unaudited)	(Audited)
Within 1 year	581	853
After 1 year but within 5 years	<u>—</u>	<u>148</u>
	<u>581</u>	<u>1,001</u>

## MANAGEMENT DISCUSSION AND ANALYSIS

### BUSINESS REVIEW

The Group is principally a Hong Kong-based brand builder, retailer and wholesaler of health and personal care products focusing on the development, marketing, sales and distribution of the branded products. For the six months ended 30 September 2025, the Group's revenue increased 14.6% to HK\$144,972,000 from HK\$126,540,000 for the six months ended 30 September 2024 (the "**Last Period**"). Meanwhile, the profit of the Group for the Period amounted to HK\$17,901,000, which represented a growth of 35.2% from HK\$13,239,000 for the Last Period.

With the impact of various geopolitical tensions and global economic uncertainties, the overall retail market in Hong Kong continued to face operational challenges during the Period. According to the statistics from the Census and Statistics Department of Hong Kong, the estimated value of total retail sales in Hong Kong for the Period raised by approximately 2.1% as compared to the Last Period. The Group's sales increased by 14.6% as compared to the Last Period, which outperformed the overall performance of the Hong Kong retail market. This was the result of the Group's effective marketing campaigns and sales channel reallocation. The Group is committed to continuously reviewing and enhancing its business plans to adapt to the changing business environment.

As at 30 September 2025, the Group had 19 specialty stores and 68 consignment counters in Hong Kong and Macau (30 September 2024: 18 specialty stores and 67 consignment counters). The Group will continue to carefully identify suitable locations for the specialty stores and other sales channels to maximise its exposure to target customers.

### FINANCIAL REVIEW

The Group generated revenue primarily from sales channels of specialty stores, consignment counters and e-commerce etc. The main types of goods are health supplement products, personal care products and honey products. During the Period, both the revenue and profit of the Group recorded a growth which is attribute to the sound sale strategies and effective controls on cost and expense. For the six months ended 30 September 2025, the Group's revenue increased by 14.6% to HK\$144,972,000 (2024: HK\$126,540,000) while recorded a consolidated profit of HK\$17,901,000, as compared to a consolidated profit of HK\$13,239,000 for the Last Period.



The increase in overall sales performance is due to (i) the launch of popular new products; (ii) the increase in the number of sales outlets compared to the Last Period; and (iii) an effective advertising and promotion strategy.

During the Period, the Group's revenue from (i) health supplement products increased by 15.1% to HK\$138,589,000 (2024: HK\$120,398,000); (ii) personal care products slightly rose by 3.3% to HK\$5,958,000 (2024: HK\$5,766,000); and (iii) honey products grew by 13.0% to HK\$425,000 (2024: HK\$376,000). The Group's revenue from sales channels of (i) specialty stores increased by 10.4% to HK\$23,197,000 (2024: HK\$21,003,000); (ii) consignment counters increased by 16.1% to HK\$105,184,000 (2024: HK\$90,636,000); (iii) e-commerce increased by 7.5% to HK\$10,715,000 (2024: HK\$9,966,000); and other sales channels increased by 19.1% to HK\$5,876,000 (2024: HK\$4,935,000).

The following table sets forth the breakdown of the Group's revenue by categories of products for the six months ended 30 September 2025 and 2024:

	For the six months ended 30 September			
	2025		2024	
	<i>HK\$'000</i>	<i>% of total revenue</i>	<i>HK\$'000</i>	<i>% of total revenue</i>
Health supplement products	138,589	95.6%	120,398	95.1%
Personal care products	5,958	4.1%	5,766	4.6%
Honey products	425	0.3%	376	0.3%
Total	<u>144,972</u>	<u>100.0%</u>	<u>126,540</u>	<u>100.0%</u>

The table below sets forth the breakdown of the Group's revenue by sales channels for the six months ended 30 September 2025 and 2024:

	For the six months ended 30 September			
	2025		2024	
	<i>HK\$'000</i>	<i>% of total revenue</i>	<i>HK\$'000</i>	<i>% of total revenue</i>
Specialty stores	23,197	16.0%	21,003	16.6%
Consignment counters	105,184	72.5%	90,636	71.6%
E-commerce	10,715	7.4%	9,966	7.9%
Other sales channels	5,876	4.1%	4,935	3.9%
Total	<u>144,972</u>	<u>100.0%</u>	<u>126,540</u>	<u>100.0%</u>

The cost of sales increased by HK\$1,962,000 or 12.1% to HK\$18,155,000 for the Period as compared to that of HK\$16,193,000 for the Last Period. The increase of cost was in line with the growth of the revenue. The gross profit margin remained stable at 87.5% for the six months ended 30 September 2025 (2024: 87.2%).

The selling and distribution expenses of the Group increased by 11.2% to HK\$87,278,000 for the six months ended 30 September 2025 (2024: HK\$78,460,000), while the general and administrative expenses of the Group increased by 15.1% to HK\$18,697,000 for the Period (2024: HK\$16,249,000). The increase was mainly due to (i) the rise of sales commission which is align with the sales performance; and (ii) the increase in depreciation of right-of-use assets which is induced by the rise in the number of specialty stores as compared to the Last Period.

During the Period, the Group's finance costs represented interest on bank borrowing amounting to HK\$27,000 (2024: HK\$43,000) and interest on lease liabilities amounting to HK\$467,000 (2024: HK\$519,000).

The Group's revenue was mainly derived from Hong Kong, Mainland China and Macau during the Period. For the six months ended 30 September 2025, income tax expense was HK\$3,780,000 (2024: HK\$2,700,000). The provision for Hong Kong Profits Tax has been provided in accordance with two-tiered profits tax rates regime; the first HK\$2,000,000 of assessable profits of a qualifying corporation of the Group is taxed at 8.25% and the assessable profits above HK\$2,000,000 are taxed at 16.5%. The assessable profits of group entities not qualified for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5%. Taxation for subsidiaries which are outside Hong Kong is charged at the appropriate current rates of taxation ruling in the relevant tax jurisdictions.

As a result of the above factors, there was a consolidated profit for the six months ended 30 September 2025 of HK\$17,901,000 as compared to a consolidated profit of HK\$13,239,000 for the Last Period.

For the six months ended 30 September 2025, the Group recorded a basic earnings per share of HK2.35 cents as compared to the basic earnings per share of HK1.74 cents for the Last Period, the calculation of which is based on the profit for the Period of HK\$17,901,000 (2024: HK\$13,239,000) and the weighted average number of 762,000,000 Shares in issue during the Period (2024: 762,000,000 Shares). No diluted earnings per Share for those periods ended 30 September 2025 and 2024 were presented as there were no potential ordinary Shares in issue for those periods ended 30 September 2025 and 2024.

## **LIQUIDITY**

The Group's financing and treasury activities are centrally managed and controlled at the corporate level. The main objective is to utilise the funding efficiently and to manage the financial risks effectively. The Group generally meets its working capital requirements from its internally generated funds, and maintains a healthy financial position.

As at 30 September 2025, the Group had net current assets and net assets of HK\$115,398,000 (31 March 2025: HK\$110,807,000) and HK\$194,427,000 (31 March 2025: HK\$191,206,000), respectively. As at 30 September 2025, the current ratio calculated based on current assets divided by current liabilities of the Group was approximately 3.5 (31 March 2025: 4.7).

Cash and cash equivalents and time deposits held by the Group amounted to HK\$101,241,000 as at 30 September 2025 (31 March 2025: HK\$88,719,000), of which HK\$82,619,000 (31 March 2025: HK\$78,723,000) was cash and cash equivalents and HK\$18,622,000 (31 March 2025: HK\$9,996,000) was non-pledged time deposits with original maturity of over three months. They were mainly denominated in Hong Kong dollars, Japanese yen, Australian dollars, Renminbi and United States dollars.

## **OTHER FINANCIAL RESOURCES AND GEARING**

As at 30 September 2025, the total outstanding bank borrowing of the Group amounted to HK\$1,837,000 (31 March 2025: HK\$2,057,000) and it is a secured bank mortgage loan. The bank mortgage loan was repayable based on scheduled repayment dates set out in the loan agreement and the last payment is on 21 August 2029.

Interest on bank borrowing is charged at floating rates. The bank borrowing of the Group are denominated in Hong Kong dollars. No financial instruments for hedging purposes were employed by the Group for the six months ended 30 September 2025 and for the year ended 31 March 2025.

As at 30 September 2025, the bank borrowing were secured by the Group's certain leasehold land and building with aggregate net carrying value of approximately HK\$27,106,000 (31 March 2025: HK\$27,586,000).

As at 30 September 2025, the Group's gearing was considered to be at a reasonable level, as the debt to equity ratio was only 0.9% (31 March 2025: 1.1%), expressed as a percentage of total bank borrowings to total net assets.

## **FOREIGN EXCHANGE EXPOSURE**

The Group is exposed to currency risk primarily through sales and purchases, which gives rise to receivables, payables and cash balances that are denominated in a foreign currency, i.e. a currency other than the functional currency of the operations to which the transactions relate. The currencies giving rise to this risk are primarily Japanese yen, Australian dollars and Renminbi. The Group currently does not have any foreign currency hedging policy. However, the Group maintains a conservative approach in treasury management by constantly monitoring foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise. The management will continue to monitor the foreign exchange exposure and will take prudent measures when needed.

## **CAPITAL COMMITMENTS**

As at 30 September 2025, the Group did not have any capital commitments (31 March 2025: Nil).

## **MAJOR INVESTMENTS, ACQUISITIONS AND DISPOSALS**

The Group had no material investments, acquisitions or disposals of subsidiaries, associates or joint ventures during the six months ended 30 September 2025 (2024: Nil).

## **CONTINGENT LIABILITIES**

As at 30 September 2025, the Group had no material contingent liabilities (31 March 2025: Nil).

## **EMPLOYEE INFORMATION**

As at 30 September 2025, the Group had 222 (30 September 2024: 232) employees, including part-time staff. The Group remunerates employees based on their performance and experience, the Group's results as well as prevailing market conditions. In addition to salary and commission payment to staff, other staff benefits include a share option scheme, discretionary bonus, staff discount on purchases and internal training.

## **DIVIDEND**

The Board has resolved not to declare an interim dividend for the six months ended 30 September 2025 (2024: Nil).

## **PROSPECTS**

The global economic landscape is expected to remain volatile in the near term, shaped by persistent geopolitical conflicts and trade tensions. Concurrently, the Hong Kong retail market is undergoing a complex transition. While recent months have shown a gentle recovery in sales figures, the sector continues to face deep-seated structural challenges, including changing consumption patterns and high operating costs.

The Group greatly appreciates the Hong Kong Government's commitment to integrating development across culture, sports and tourism. This strategy, which promotes the concept of "Tourism is Everywhere" and strengthens the mega-event economy, is pivotal for attracting more visitors. It is believed that this will be instrumental in converting foot traffic into sustained business growth, thereby revitalising the broader retail market.

To leverage on all the practical initiatives, the Group will actively embrace digital and technological transformation. By adopting advanced digital tools, the operation process can be streamlined to enhance efficiency. Sales data can be thoroughly analysed to gain valuable insights into evolving customer preferences and deliver specific product information to targeted customers to increase sales effectiveness.

The Group will continue to diversify the product portfolio by providing new products to serve customers of various preferences. Each step of the product development process is sophisticatedly planned and executed to ensure products of superior quality are consistently delivered.

Every era presents its own set of challenges and opportunities. The Group will continue to advance strategically with an unwavering dedication to sustainable, long-term business development.

## **CORPORATE GOVERNANCE AND OTHER INFORMATION**

### **SHARE OPTION SCHEME**

Pursuant to the written resolution of the sole Shareholder passed on 20 July 2016, the Company adopted a share option scheme (the "**Scheme**") conditional upon the Listing. The Scheme became effective on 12 September 2016. As no share options have been granted under the Scheme since its adoption, there were no outstanding share options as at 30 September 2025, and no share options were exercised or cancelled or lapsed during the Period.

As at 1 April 2025 and 30 September 2025, the number of share options under the Scheme available to be granted are 75,000,000 Shares, respectively.

## **PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES**

Throughout the Period, the Company did not redeem its listed securities, nor did the Company or any of its subsidiaries purchase or sell such securities (including sale of treasury share, if any).

As at 30 September 2025, the Company did not hold any treasury shares.

## **ARRANGEMENTS TO PURCHASE SHARES OR DEBENTURES**

At no time during the Period or at the end of the Period was the Company, or its holding company or any of its subsidiaries or fellow subsidiaries, a party to any arrangements to enable the Directors to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate.

## **CORPORATE GOVERNANCE CODE**

The Company has complied with the mandatory disclosure requirements and all the applicable code provisions as set out in the section headed “Part 2 — Principles of good corporate governance, code provisions and recommended best practices” of the Corporate Governance Code contained in Appendix C1 to the Listing Rules (the “**CG Code**”) throughout the Period save for the deviation from code provision C.2.1 as follows:

Under code provision C.2.1 of the CG Code, the roles of the chairman and the chief executive should be separate and should not be performed by the same individual.

In view of the present composition of the Board, the in-depth knowledge of the chairman of the Board (the “**Chairman**”) (who is also a co-chief executive officer) of the operations of the Group and the health and personal care industry in general, his extensive business network and connections, and the scope of operations of the Group, the Board believes that it is in the best interest of the Group for Mr. Choy Chi Fai to assume the roles of both the Chairman and the co-chief executive officer. As all major decisions are made in consultation with all the members of the Board, with the independent non-executive Directors offering independent perspectives, the Board believes that there are adequate safeguards in place to ensure sufficient balance of powers within the Board.

## **MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS**

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules (the “**Model Code**”) as its own code of conduct regarding Directors’ securities transactions. Having been made specific enquiries by the Company, all Directors confirmed that they had complied with the required standard set out in the Model Code throughout the Period.

## **SUFFICIENCY OF PUBLIC FLOAT**

According to the information that is publicly available to the Company and within the knowledge of the Directors, the percentage of the Shares which are in the hands of the public is not less than 25% of the Company's total number of issued Shares throughout the Period.

## **AUDIT COMMITTEE**

The principal duties of the Audit Committee include the review and supervision of the Group's financial reporting system and internal control procedures and review of the Group's financial information.

The Audit Committee has reviewed the unaudited condensed consolidated interim financial results of the Group for the Period and this announcement with the Directors.

## **APPRECIATION**

On behalf of the Board, I would like to express our gratitude to the Shareholders, business partners and customers for their continuing support, and extend our sincere appreciation to all management and staff for their ongoing dedication, commitments and contributions.

By Order of the Board  
**Ausupreme International Holdings Limited**  
**Choy Chi Fai**

*Chairman, Executive Director and Co-Chief Executive Officer*

Hong Kong, 26 November 2025

*As at the date of this announcement, the Board comprises two Executive Directors, namely Mr. Choy Chi Fai (Chairman and Co-Chief Executive Officer) and Ms. Ho Ka Man (Vice Chairman and Co-Chief Executive Officer); and three Independent Non-executive Directors, namely Prof. Luk Ting Kwong, Dr. Wan Cho Yee and Ms. Pang Sin Mei Ada.*

*In case of any inconsistency between the English and Chinese versions, the English text of this announcement shall prevail over the Chinese text.*